Education / Graduate Medical Education / Prospective Fellows / Infectious Diseases Fellowship / Research / Peer Reviewed Publications Recent Peer Reviewed Publications Garrett NDintwe OMonaco CLJones MSeaton KEChurch ECGrunenberg NHutter JdeCamp AHuang YLu HMann PRobinson STHeptinstall JJensen RLPantaleo GDing SKoutsoukos MHosseinipour MCVan Der Meeren OGilbert PBFerrari GAndersen-Nissen EMcElrath MJTomaras GDGray GECorey LKublin JG Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.; Journal of acquired immune deficiency syndromes (1999); Vol 96(4), pp. 350-360. 2024 Jun 21. Hahn WOParks KRShen MOzorowski GJanes HBallweber-Fleming LWoodward Davis ASDuplessis CTomai MDey AKSagawa ZKDe Rosa SCSeese ASiddaramaiah LKStamatatos LLee WHSewall LMKarlinsey DTurner HLRubin VFurth SMacPhee KDuff MCorey LKeefer MCEdupuganti SFrank IMaenza JBaden LRHyrien OSanders RWMoore JPWard ABTomaras GDMontefiori DCRouphael NMcElrath MJ HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies.; medRxiv : the preprint server for health sciences. 2024 May 09. Fisher LHKee JJLiu AEspinosa CMRandhawa AKLudwig JMagaret CARobinson STGilbert PBHyrien OKublin JGRouphael NFalsey ARSobieszczyk MEEl Sahly HMGrinsztejn BGray GEKotloff KLGay CLLeav BHirsch IStruyf FDunkle LMNeuzil KMCorey LHuang YGoepfert PAWalsh SRBaden LRJanes H SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.; JAMA network open; Vol 7(5), pp. e2412835. 2024 May 01. Singh KRubenstein KCallier VShaw-Saliba KRupert ADewar RLaverdure SHighbarger HLallemand PHuang MLJerome KRSampoleo RMills MGGreninger ALJuneja KPorter DBenson CADempsey WEl Sahly HMFocht CJilg NPaules CIRapaka RRUyeki TMLane HCBeigel JDodd LE SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.; The Journal of infectious diseases. 2024 Apr 24. Davis ECMonaco CInsel RJärvinen KM Gut microbiome in the first 1000 days and risk for childhood food allergy.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2024 Mar 15. Li JZMelberg MKittilson AAbdel-Mohsen MLi YAga EBosch RJWonderlich ERKinslow JGiron LBDi Germanio CPilkinton MMacLaren LKeefer MFox LBarr LAcosta EAnanworanich JCoombs RMellors JDeeks SGandhi RTBusch MLanday AMacatangay BSmith DM Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.; JCI insight; Vol 9(3). 2024 Feb 08. Miner MDdeCamp AGrunenberg NDe Rosa SCFiore-Gartland ABar KSpearman PAllen MYu PCManso BFrahm NKalams SBaden LKeefer MCScott HMNovak RVan Tieu HTomaras GDKublin JGMcElrath MJCorey LFrank I Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial.; EBioMedicine; Vol 100, pp. 104987. 2024 Feb 01. Luther VPParas MLSchultz SAziz MBalba GMcCarty TPRazonable RRReece RShnekendorf RSundareshan VChirch LM High-Volume, High-Acuity, and High-Impact Learning: Tips and Tricks for Infectious Diseases Training Programs.; Open forum infectious diseases; Vol 11(3), pp. ofae016. 2024 Jan 08. Rick AMLaurens MBHuang YYu CMartin TCSRodriguez CARostad CAMaboa RMBaden LREl Sahly HMGrinsztejn BGray GEGay CLGilbert PBJanes HEKublin JGHuang YLeav BHirsch IStruyf FDunkle LMNeuzil KMCorey LGoepfert PAWalsh SRFollmann DKotloff KL Risk of COVID-19 after natural infection or vaccination.; EBioMedicine; Vol 96, pp. 104799. 2023 Sep 20. Rouphael NWinokur PKeefer MCTraenkner JDrobeniuc ADoi YMunsiff SFowler VGEvans SOler RETuyishimire BLee MGhazaryan VChambers HF Daily fosfomycin versus levofloxacin for complicated urinary tract infections.; mBio. 2023 Sep 12. Branche ARRouphael NGDiemert DJFalsey ARLosada CBaden LRFrey SEWhitaker JALittle SJAnderson EJWalter EBNovak RMRupp RJackson LABabu TMKottkamp ACLuetkemeyer AFImmergluck LCPresti RMBäcker MWinokur PLMahgoub SMGoepfert PAFusco DNMalkin EBethony JMWalsh EEGraciaa DSSamaha HSherman ACWalsh SRAbate GOikonomopoulou ZEl Sahly HMMartin TCSKamidani SSmith MJLadner BGPorterfield LDunstan MWald ADavis TAtmar RLMulligan MJLyke KEPosavad CMMeagher MAStephens DSNeuzil KMAbebe KHill HAlbert JTelu KMu JLewis TCGiebeig LAEaton ANetzl AWilks SHTüreli SMakhene MCrandon SMontefiori DCMakowski MSmith DJNayak SURoberts PCBeigel JH Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.; Nature medicine. 2023 Aug 28. Rouphael NGBranche ARDiemert DJFalsey ARLosada CBaden LRFrey SEWhitaker JALittle SJKamidani SWalter EBNovak RMRupp RJackson LABabu TMKottkamp ACLuetkemeyer AFImmergluck LCPresti RMBäcker MWinokur PLMahgoub SMGoepfert PAFusco DNAtmar RLPosavad CMNetzl ASmith DJTelu KMu JMcQuarrie LJMakowski MMakhene MKCrandon SMontefiori DCRoberts PCBeigel JH Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.; The Journal of infectious diseases. 2023 Aug 10. de Bruyn GWang JPurvis ARuiz MSAdhikarla HAlvi SBonaparte MIBrune DBueso ACanter RMCeregido MADeshmukh SDiemert DFinn AForrat RFu BGallais JGriffin PGrillet MHHaney OHenderson JAKoutsoukos MLaunay OTorres FMMasotti RMichael NLPark JRivera-Medina DMRomanyak NRook CSchuerman LSher LDTavares-Da-Silva FWhittington AChicz RMGurunathan SSavarino SSridhar S Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.; EClinicalMedicine; Vol 62, pp. 102109. 2023 Jul 22. Falsey ARWalsh EE Respiratory syncytial virus Prefusion F vaccine.; Cell; Vol 186(15), pp. 3137-3137.e1. 2023 Jul 20. Lyke KEAtmar RLDominguez Islas CPosavad CMDeming MEBranche ARJohnston CEl Sahly HMEdupuganti SMulligan MJJackson LARupp RERostad CAColer RNBäcker MKottkamp ACBabu TMDobrzynski DMartin JMBrady RCFrenck RWRajakumar KKotloff KRouphael NSzydlo DPaulChoudhury RArcher JICrandon SIngersoll BEaton ABrown ERMcElrath MJNeuzil KMStephens DSPost DJLin BCSerebryannyy LBeigel JHMontefiori DCRoberts PC Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.; NPJ vaccines; Vol 8(1), pp. 98. 2023 Jul 11.